18.02

0.95% +0.17

Tyra Biosciences Inc (TYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Tyra Biosciences Inc stock is currently priced at $18.02, with a 24-hour trading volume of 537. It has seen a +0.95% increased in the last 24 hours and a +0.11% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $18.19 pivot point. If it approaches the $17.09 support level, significant changes may occur.

Previous Close:

$17.85

Open:

$17.83

24h Volume:

537

Market Cap:

$937.55M

Revenue:

Net Income/Loss:

$-69.13M

P/E Ratio:

-15.02

EPS:

-1.2

Net Cash Flow:

$-50.91M

1W Performance:

+9.54%

1M Performance:

+0.11%

6M Performance:

+40.78%

1Y Performance:

+45.09%

1D Range:

$17.50

$17.83

52W Range:

$10.38

$20.67

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name

Tyra Biosciences Inc

Sector

Healthcare (1214)

Industry

Biotechnology (699)

Phone

619-728-4760

Address

2656 State Street, Carlsbad

Employee

Twitter

Next Earnings Date

2024-05-29

Latest SEC Filings

TYRA's Discussions on Twitter

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-30-23	Initiated	Wedbush	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Jun-23-22	Initiated	H.C. Wainwright	Buy
Mar-08-22	Upgrade	Jefferies	Hold → Buy
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	BofA Securities	Buy
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	Jefferies	Buy

View All

Tyra Biosciences Inc Stock (TYRA) Latest News

S&P 500 Gains Over 1%; Amazon Earnings Top Expectations

Benzinga

Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Nasdaq Rises Over 200 Points; Apple Posts Upbeat Earnings

Benzinga

Clorox Posts Upbeat Earnings, Joins Cigna, Deckers Outdoor And Other Big Stocks Moving Higher On Friday

Benzinga

Chegg, Perdoceo Education And Other Big Stocks Moving Lower On Monday

Benzinga

Tyra Biosciences Inc Stock (TYRA) Financials Data

Tyra Biosciences Inc (TYRA) Net Income 2024

TYRA net income (TTM) was -$69.13 million for the quarter ending December 31, 2023, a -24.96% decrease year-over-year.

Tyra Biosciences Inc (TYRA) Cash Flow 2024

TYRA recorded a free cash flow (TTM) of -$50.91 million for the quarter ending December 31, 2023, a -0.13% decrease year-over-year.

Tyra Biosciences Inc (TYRA) Earnings per Share 2024

TYRA earnings per share (TTM) was -$1.61 for the quarter ending December 31, 2023, a -21.05% decline year-over-year.

Tyra Biosciences Inc Stock (TYRA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Bensen Daniel	Chief Operating Officer	Mar 07 '24	Sale	20.00	68	1,360	431,883
Bensen Daniel	Chief Operating Officer	Mar 06 '24	Sale	20.09	1,733	34,819	431,951
Bensen Daniel	Chief Operating Officer	Mar 05 '24	Sale	20.02	1,189	23,802	433,684
Bensen Daniel	Chief Operating Officer	Mar 04 '24	Sale	20.08	5,063	101,654	434,873
Bensen Daniel	Chief Operating Officer	Mar 01 '24	Sale	20.04	2,900	58,112	439,936
Bensen Daniel	Chief Operating Officer	Feb 29 '24	Sale	20.00	2,050	41,003	442,836
Bensen Daniel	Chief Operating Officer	Feb 28 '24	Sale	20.13	5,849	117,729	444,886
Bensen Daniel	Chief Operating Officer	Feb 27 '24	Sale	20.00	745	14,900	450,735
Bensen Daniel	Chief Operating Officer	Feb 12 '24	Sale	20.00	1,501	30,020	451,480
Bensen Daniel	Chief Operating Officer	Feb 07 '24	Sale	18.09	9,587	173,466	452,981

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.